Back to Solutions

Entity Value (CEA)

Comprehensive CEA for healthcare intervention/technology value assessment - ICER, Budget Impact, PSA included

Problem Statement

When deciding whether to adopt new drugs, medical devices, or treatment protocols, quantitative cost-effectiveness evaluation is essential. A complete CEA package including QALY, ICER, budget impact, and uncertainty analysis is required, not just simple cost savings.

Common Decisions

  • Prioritizing new drug/device adoption
  • Preparing economic evaluation for reimbursement application
  • Cost-effectiveness analysis of treatment protocol changes
  • Optimal portfolio selection under budget constraints
  • Value demonstration to insurers/government (Value Dossier)

Required Inputs

* Minimal internal data possible

  • 1Intervention/technology cost data (unit price, frequency)
  • 2Clinical effectiveness data (RCT, RWE, meta-analysis)
  • 3Existing standard treatment (Comparator) information
  • 4Target patient population size and characteristics
  • 5Payer perspective (hospital, insurer, government)
  • 6Analysis parameters (discount rate, time horizon, etc.)

Output Spec

Decision Packet Components

  • CEA (Cost-Effectiveness Analysis)

    Cost-benefit analysis - ICER, CE plane, ranking

  • BIA (Budget Impact Analysis)

    Budget impact - annual fiscal requirements and cumulative impact

  • Uncertainty (PSA)

    Probabilistic sensitivity analysis - CEAC, confidence intervals, scenario analysis

  • Audit (Decision Log)

    Decision tracking - assumptions, data sources, model structure

Typical Timeline

2 weeks

Diagnostic Phase

Literature review, data acquisition, model structure design, comparator definition

4-6 weeks

Analysis Phase

CEA model building, scenario analysis, PSA execution, results compilation and report writing

Security & Deployment

  • Sensitive clinical data separation and anonymization
  • Analysis result versioning and history tracking
  • Documentation ready for academic/regulatory submission
  • NDA-based external disclosure scope management

Package

Decision Brief

Executive summary (1-2p) for decision-makers

CEA Report

Complete CEA analysis - ICER, BIA, PSA, sensitivity included

Audit Pack

Assumptions, model structure, data sources - for academic/regulatory submission